The Parkinsonian neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on membrane currents and intrasynaptosomal calcium

Neuroscience Research Communications

Volumn 30, Issue 1, 2002, Pages 35-42

  Mohanakumar, K P ^a   Samanta Ray, S ^a   Busselberg D ^b  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Dopamine, MPP+; Neurotoxicity; Patch clamp studies; Voltage activated K+ currents

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CALCIUM; FURA 2 ACETOXYMETHYL ESTER; ION CHANNEL; NEUROTOXIN; PYRIDINIUM DERIVATIVE;

ANIMAL CELL; ARTICLE; CALCIUM MOBILIZATION; CONTROLLED STUDY; ELECTRIC POTENTIAL; MEMBRANE CURRENT; NERVE MEMBRANE; NEUROTOXICITY; NEWBORN; NONHUMAN; PARKINSON DISEASE; PATCH CLAMP; POTASSIUM CURRENT; RAT; SPINAL GANGLION; SYNAPTOSOME;

EID: 0036125730     PISSN: 08936609     EISSN: None     Source Type: Journal    
DOI: 10.1002/nrc.10015     Document Type: Article

References (29)

1. Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydroxypyridine (MPTP) on ganglionic transmission
2. Protective effect of riluzole on MPTP-induced depletion of dopamine and its metabolite content in mice
3. Riluzole delayed appearance of parkinsonian motor abnormalities in a chronic MPTP monkey model
4. Zinc blocks voltage- gated channels in cultured rat dorsal root ganglion cells
5. + enhances potassium evoked striatal dopamine release through a ω-conotoxin-insensitive, tetradotoxin- and nimodipine-sensitive calcium dependent mechanism
6. Role of dopamine autoxidation, hydroxyl radical generation and calcium overload in underlying mechanisms involved in MPTP-induced parkinsonism
7. In vivo formation of hydroxyl radicals and MPTP-induced dopaminergic toxicity in the basal ganglia
8. Implication of poly (ADP-ribose) polymerase (PARP) in neurodegeneration and brain energy metabolism. Decreases in mouse brain NAD+ and ATP caused by MPTP are prevented by the PARP inhibitor benzamide
9. +: Implication for neurodegeneration
10. 2 and ATP production and on dopamine and DOPAC in the striatum
11. Mitochondrial dysfunction in Parkinson's disease
12. 2+ indicators with greatly improved fluorescence properties
13. Inhibition of neuronal nitric oxide synthase protects against MPTP toxicity
14. Pretreatment with nimodipine prevents MPTP-induced neurotoxicity at the nigral, but not at the striatal level in mice
15. + and paraquat on mitochondrial potential and oxidative stress
16. Mid-brain dopaminergic neurons in the mouse that contain calbindin-D28k exhibit reduced vulnerability to MPTP-induced neurodegeneration
17. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease
18. Resistance of golden hamster to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: Relationship with low levels of regional monoamine oxidase-B
19. Hydroxyl radicals and nitric oxide in neurotoxicity and neuroprotection
20. Neurochemical mechanisms underlying neuroprotective actions of bromocriptine, salicylate, D- and L-deprenyl in neurodegeneration caused by MPTP
21. Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced neurotoxicity in mice
22. +) in the neostriatum of the rat as demonstrated in vivo by the push-pull perfusion technique: Dependence of sodium, but not calcium ions
23. In vitro studies of striatal vesicles containing the vesicular monoamine transporter (VMAT2): Rat versus mouse differences in sequestration of 1-methyl-4-phenylpyridinium
24. In vivo hydroxyl radical generation in the striatum following systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice
25. + neurotoxicity by N-methyl-D-aspartate antagonists
26. Dopamine transporter function assessed by antisense knockdown in the rat: Protection from dopamine neurotoxicity
27. Presence of catecholamine-related enzymes in a subpopulation of primary sensory neurons in dorsal root ganglia of the rat
28. Detection of mRNAs and alternatively spliced transcripts of dopamine receptors in rat peripheral sensory and sympathetic ganglia
29. The pharmacological profile of the vesicular monoamine transporter resembles that of multidrug transporters